文献速递其他结缔组织病

靶向PD-1通路可减轻系统性硬化症中炎症驱动的纤维化

Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis.
PubMed 文献 · Ann Rheum Dis · 2026-02-10

该研究探讨PD-1通路对弥漫性皮肤型系统性硬化症(dcSSc)免疫激活和纤维化的影响。体外实验显示PD-1:Fc可下调TGF-β刺激的dcSSc成纤维细胞分泌细胞外基质蛋白、活化标志物和炎性细胞因子,小鼠博来霉素模型中PD-1:Fc抑制肺纤维化及促纤维化细胞因子产生。结论提示调节PD-1/PD-L1轴可能成为dcSSc的新治疗途径。

要点

  • dcSSc患者血清可溶性PD-1及细胞PD-1较健康对照升高。
  • PD-1:Fc体外下调TGF-β刺激的dcSSc成纤维细胞ECM蛋白和炎性细胞因子。
  • 小鼠博来霉素模型中PD-1:Fc抑制肺纤维化和促纤维化细胞因子。

核心结论

  • 给予PD-1:Fc在dcSSc体外模型中减轻炎症和ECM蛋白产生,并在小鼠博来霉素诱导纤维化模型中减少全身炎症和肺纤维化,提示调节PD-1/PD-L1轴是dcSSc的新治疗途径。

研究设计与样本

  • 研究获取dcSSc患者和健康对照(HCs)的血液和皮肤活检,检测血清可溶性PD-1。
  • 使用人重组PD-1蛋白(PD-1:Fc)和抗PD-1抗体刺激外周血单核细胞(PBMCs)、HC和SSc真皮成纤维细胞培养及共培养,并表征dcSSc PBMCs中PD-1阳性和PD-1阴性群体。
  • 采用小鼠博来霉素肺损伤模型在体内研究PD-1:Fc对肺纤维化的影响。

主要发现

  • 与HC相比,dcSSc中可溶性和细胞PD-1升高。
  • HC与dcSSc的初始成纤维细胞存在差异,但不对PD-1:Fc治疗产生反应。
  • 来自dcSSc的TGF-β刺激成纤维细胞显示肌成纤维细胞表型,与HC成纤维细胞相比聚类不同。
  • PD-1:Fc下调TGF-β刺激的体外培养中细胞外基质(ECM)蛋白分泌、成纤维细胞活化表面标志物和炎性细胞因子产生。
  • PD-1阳性SSc T细胞较PD-1阴性T细胞群体具有不同且更调节性的转录谱。

临床怎么用

  • 本研究为体外和小鼠模型临床前证据,暂不支持直接用于dcSSc临床实践。
  • PD-1:Fc在TGF-β刺激的dcSSc成纤维细胞中下调ECM蛋白和炎性细胞因子,提示调节PD-1/PD-L1轴是潜在治疗方向。
  • 小鼠博来霉素模型中PD-1:Fc抑制肺纤维化和促纤维化细胞因子,支持进一步转化研究。

局限性

  • 研究主要为体外实验和小鼠博来霉素模型,尚未在dcSSc患者中验证PD-1:Fc的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study elucidates the impact of the programmed cell death protein 1 (PD-1) pathway on immune activation and fibrosis in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo. RESULTS: Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines. CONCLUSIONS: Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Aspari M, Ong V, Søndergaard K, et al. Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis. Ann Rheum Dis. 2026. PMID: 41667322. doi:10.1016/j.ard.2026.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。